Treatment-experienced people

Treatment-experienced people features

• 

  The generic generation

  In the next few years, some of the most widely used HIV drugs will come off patent in the UK. Gus Cairns asks: what are the...

  From:  HIV treatment update

Treatment-experienced people in your own words

• 

  TB - my experiences

  This might sound odd, but I was really shocked when I became seriously ill because of HIV. I was even more shocked when it turned...

  From: In your own words

• 

  Living with HIV and hep C co-infection and haemophilia

  For most people, coping with HIV is enough of a problem in itself, but when you throw in a lifetime disorder such as haemophilia, and...

  From: In your own words

• 

  Finally undetectable!

  After almost 15 years of HIV, and six years of viral load testing, I heard on Thursday, June 21st 2001 that my viral load had...

  From: In your own words

Treatment-experienced people news from aidsmap

• ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available

  Treatment for HIV-positive individuals with persistent viral replication despite therapy with multiple regimens is effective and safe over two years when it omits nucleoside reverse transcriptase inhibitors (NRTIs), provided patients have three active alternative drugs available, according to research published ...

  13 June 2019 | Michael Carter

• Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

  The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual classes. Despite the overall success of antiretrovirals (ARVs), there remain a minority ...

  07 November 2018 | Gus Cairns

• Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

  A treatment regimen containing ibalizumab (Trogarzo), a monoclonal antibody designed to block HIV, led to substantial viral load reductions in a majority of highly treatment-experienced people with few treatment options left, Dr Zvi Cohen of Theratechnologies reported at the ...

  02 November 2018 | Keith Alcorn

• Ibalizumab, active against highly resistant HIV, now approved in US

  Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, is active against virus strains that have developed resistance to multiple other antiretrovirals, according to a poster presentation at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) ...

  08 March 2018 | Liz Highleyman

• Fostemsavir controls viral load in half of people with highly drug-resistant HIV

  Fostemsavir, a new experimental attachment inhibitor, suppressed viral load in over half of participants with extensive drug resistance when added to a background regimen selected by resistance testing, Max Lataillade of ViiV Healthcare reported at the 16th European AIDS Conference ...

  28 October 2017 | Keith Alcorn

• Long-acting monoclonal antibody effective against multidrug-resistant HIV

  Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited treatment options, according to a presentation at the IDWeek 2017 conference ...

  12 October 2017 | Liz Highleyman

• First protease inhibitor combination pill maintains viral suppression

  The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report at the 9th International AIDS Society ...

  01 August 2017 | Liz Highleyman

• New HIV capsid inhibitors show high potency and prolonged activity in early studies

  A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer a new potent and long-acting treatment option if it continues to look ...

  03 March 2017 | Liz Highleyman

• Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV

  Ibalizumab, an experimental monoclonal antibody with a unique mechanism of action, demonstrated good safety and promising efficacy in a small phase 3 study of people with extensive drug resistance who cannot be successfully treated with available therapies, according to ...

  04 November 2016 | Liz Highleyman

• HIV salvage regimens can safely omit NRTIs, says US study

  Nucleoside reverse transcriptase inhibitors (NRTIs) can be safely omitted from HIV salvage therapy, investigators from the United States report in the Annals of Internal Medicine. The findings come from a randomised study conducted between 2008 and 2011.The study population ...

  04 January 2016 | Michael Carter

More news

Treatment-experienced people news selected from other sources

• Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

  Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.

  20 March 2019 | Poz

• South Africa: Shortage of drug puts thousands of Aids patients at risk

  Health authorities have confirmed the shortage of Darunavir, a third-line drug. Third-line drugs are used when patients have few drug options left to treat their condition.

  15 March 2019 | Independent Online

• Can high-dose dolutegravir be a rescue therapy?

  A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

  12 March 2019 | CATIE

• Ibalizumab Provides New Option for Patients with Multidrug-Resistant HIV

  A newly published phase 3 study of patients with multidrug-resistant (MDR) HIV shows that ibalizumab can be a safe and effective option for patients with limited other avenues of treatment.

  23 August 2018 | MD Magazine

• New HIV therapy reduces virus, boosts immunity in drug-resistant patients

  Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

  16 August 2018 | Science Daily

• Nelson Vergel: Built to Survive

  “There’s wisdom with age, but there’s a lot more wisdom with age and HIV,” says Nelson Vergel. Like many long-term survivors, he initially considered his HIV diagnosis a death sentence. But despite the odds, the Venezuelan immigrant refused to give up.

  29 June 2018 | Poz

• FDA approves new HIV treatment for patients who have limited treatment options

  Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

  07 March 2018 | FDA

• CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection

  CytoDyn Inc. (OTC.QB:CYDY) reports the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral therapy (ART) in patients failing their current HIV therapy. The trial data show a statistically significant reduction in HIV-1 RNA viral load of greater than 0.5log with PRO 140 versus placebo. CytoDyn is developing PRO 140, a humanized CCR5 monoclonal antibody, to combat human immunodeficiency virus (HIV) infection and certain immunologic disorders.

  21 February 2018 | CytoDyn press release

• Antibody-Based HIV Tx Proves Durable

  The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

  10 October 2017 | MedPage Today

• People With Multidrug-Resistant HIV Can Now Start Treatment on the Experimental Drug Ibalizumab

  Ibalizumab is a new drug that is effective against drug resistant HIV. It is not approved for sale in the United States, but patients can take advantage of an expanded access program to start treatment right away.

  15 December 2016 | TheBody.com

More news